Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.00-0.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.88M | 81.71M | 63.76M | 57.80M | 52.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.88M | 81.71M | 63.76M | 57.80M | 52.29M |
| Cost of Revenue | 103.71M | 103.30M | 100.44M | 111.52M | 138.75M |
| Gross Profit | -70.83M | -21.59M | -36.68M | -53.72M | -86.46M |
| SG&A Expenses | 36.89M | 37.75M | 42.92M | 44.63M | 48.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.60M | 141.05M | 143.36M | 156.15M | 186.81M |
| Operating Income | -107.73M | -59.34M | -79.60M | -98.35M | -134.52M |
| Income Before Tax | -109.35M | -63.50M | -79.60M | -98.11M | -134.85M |
| Income Tax Expenses | -442.00K | -193.00K | -146.00K | -167.00K | -12.00K |
| Earnings from Continuing Operations | -108.91 | -63.31 | -79.45 | -97.94 | -134.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.91M | -63.31M | -79.45M | -97.94M | -134.84M |
| EBIT | -107.73M | -59.34M | -79.60M | -98.35M | -134.52M |
| EBITDA | -103.48M | -54.87M | -74.88M | -93.24M | -128.83M |
| EPS Basic | -0.44 | -0.28 | -0.38 | -0.51 | -0.74 |
| Normalized Basic EPS | -0.28 | -0.17 | -0.23 | -0.30 | -0.44 |
| EPS Diluted | -0.45 | -0.29 | -0.39 | -0.52 | -0.74 |
| Normalized Diluted EPS | -0.28 | -0.17 | -0.23 | -0.30 | -0.44 |
| Average Basic Shares Outstanding | 991.67M | 895.75M | 842.75M | 802.82M | 770.25M |
| Average Diluted Shares Outstanding | 991.67M | 901.73M | 848.73M | 808.80M | 776.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |